Nigel S. Key

Fewer severe infections with tranexamic acid in patients with hematologic malignancies

Susanne May, Anton Ilich, Christopher E. Jensen, Jacqueline N. Poston et autres

us (code pays fourni par la source)

Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years

Sandra Le Quellec, Paul E. Monahan, Esteban Gomez, Nigel S. Key et autres

Etranacogene dezaparvovec (CSL222, formerly AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the highly active factor IX (FIX) Padua variant controlled by a liver-specific promoter. This Phase 2b, open-label, single-dose, single-arm, multi-center trial evaluated the efficacy and safety of …

us (code pays fourni par la source)

Addressing the Pathophysiology of Venous Thrombosis and Chronic Kidney Disease in Sickle Cell Trait Using a Mouse Model

Nigel S. Key, Vimal K. Derebail, Małgorzata Kasztan, Fatima Trebak et autres

Sickle cell trait (SCT) is present in subjects who possess a single copy of the bS-globin gene mutation. While most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. …

us (code pays fourni par la source)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype

David Lillicrap, Barbara Zieger, R Lassila, Alessandro Casini et autres

In a previous paper, a comprehensive clinicopathologic approach to mild and moderate bleeding disorders (MBD) was proposed by an international working group (IWG) as a part of a project promoted by the European Hematology Association (EHA) on the development of guidelines on …

us (code pays fourni par la source)

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results

H Yu, Margareth C. Ozelo, Adam Giermasz, Robert Klamroth et autres

us (code pays fourni par la source)

Rapid Detection of Fibrinolytic Activation in Postpartum Hemorrhage and Acute Obstetric Coagulopathy Using a Novel Assay.

Peter V Jenkins, Supreet Kaur Goraya, Callie Berkowitz, Claire S. Whyte et autres

Postpartum hemorrhage (PPH) remains the leading cause of pregnancy-related mortality worldwide. Regardless of initiating cause, continued bleeding may progress to a systemic coagulopathy. This coagulopathy may be further complicated by profound fibrinolytic activation progressing to systemic hyperfibrinolysis, a condition that we have …

us (code pays fourni par la source)

Real‐world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi

Kate D. Westmoreland, Wiza Kumwenda, Msandeni Chiume, Gerald Tegha et autres

INTRODUCTION: Sickle cell disease (SCD) is among the most common inherited hematologic diseases in sub-Saharan Africa (SSA). Historically, hydroxyurea administration in SSA has been restricted due to limited region-specific evidence for safety and efficacy. METHODS: We conducted a prospective observational cohort study …

us (code pays fourni par la source)

Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors

Steven P. Grover, Kiril Tenekedjiev, Cihan Ay, Anaum Maqsood et autres

Pancreatic cancer is associated with a high incidence of venous thromboembolism. Neutrophils have been shown to contribute to thrombosis in part by releasing neutrophil extracellular traps (NET). A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 …

us (code pays fourni par la source)

Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer

Anton Ilich, Raj S. Kasthuri, Nigel S. Key, Yohei Hisada et autres

us (code pays fourni par la source)

Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma

N. Mackman, Staffan Lundström, Zu‐Wen Sun, Denis F. Noubouossie et autres

us (code pays fourni par la source)

Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group

Nigel Mackman, Keith R. McCrae, Gilbert White, Owen J T McCarty et autres

The risk for venous thromboembolism (VTE) is increased in cancer and particularly with chemotherapy, and it portends poorer survival among patients with cancer. However, many fundamental questions about cancer-associated VTE, or Trousseau syndrome, remain unanswered. This report summarizes the proceedings of a …

us (code pays fourni par la source)

Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles

David Schiff, Itay Tirosh, Shilpa Chennakrishnaiah, Steven P. Grover et autres

Vascular anomalies, including local and peripheral thrombosis, are a hallmark of glioblastoma (GBM) and an aftermath of deregulation of the cancer cell genome and epigenome. Although the molecular effectors of these changes are poorly understood, the upregulation of podoplanin (PDPN) by cancer …

us (code pays fourni par la source)